The Anorectal Function and QoL of Patients Receiving Transrectal NOSE Via Rigid TAMIS Platform in Minimal Invasive Colon Surgery
2026年6月15日 更新者:Chang Gung Memorial Hospital
A Prospective, Multi-Center, Single-Arm, Open-Label Study to Analyze Anorectal Function and Quality of Life in Patients Undergoing Minimally Invasive Colectomy With Transrectal Natural Orifice Specimen Extraction (NOSE) Using a Rigid Transanal Minimally Invasive Surgery (TAMIS) Platform
The primary objective of this study is to prospectively determine and precisely estimate the incidence of Internal Anal Sphincter (IAS) Injury at 12 months following colectomy with Transrectal NOSE.
研究概览
研究类型
介入性
注册 (估计的)
57
阶段
- 不适用
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
不
描述
Inclusion Criteria:
- Male or female, aged above 18 years, inclusive.
- Patients scheduled for an elective laparoscopic or robotic-assisted colectomy above sigmoid colon.
- Deemed a suitable candidate for the Transrectal NOSE procedure by the treating surgical team, based on tumor size (generally, largest diameter < 4 cm), tumor T stage(1-3), location, and patient anatomy.
- American Society of Anesthesiologists (ASA) physical status classification of I, II, or III.
- Able to understand the purpose, procedures, potential risks, and benefits of the study and willing to provide written informed consent, as approved by the Institutional Review Board (IRB).
- Willing and able to comply with all scheduled follow-up visits and assessment procedures outlined in the protocol.
Exclusion Criteria:
- Pre-existing moderate-to-severe fecal incontinence, defined as a Wexner incontinence score > 8.
- History of any prior anal surgery (e.g., sphincteroplasty, artificial sphincter implantation, fistulotomy), major pelvic surgery (e.g., hysterectomy, radical prostatectomy), or pelvic radiation therapy.
- Confirmed diagnosis of Inflammatory Bowel Disease (Crohn's disease or ulcerative colitis).
- The planned surgical procedure requires a protective stoma.
- Uncorrectable coagulopathy identified on preoperative assessment.
- Known neurological condition affecting bowel control (e.g., spinal cord injury, multiple sclerosis, significant post-stroke deficits).
- Cognitive impairment, severe psychiatric illness, or other condition that would interfere with reliable completion of questionnaires or compliance with the protocol.
- Currently pregnant, breastfeeding, or planning to become pregnant during the study period.
- Concurrent participation in another interventional clinical trial that could potentially interfere with the study outcomes.
- Any other condition which, in the professional opinion of the investigator, makes the subject unsuitable for participation in this study.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Patients receiving minimal invasive colon surgery with transrectal NOSE via rigid TAMIS platform
|
Pre-op and post-op anorectal function, rectal ultrasound and quality of life evaluation via questionaires
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
The incidence of Internal Anal Sphincter (IAS) injury
大体时间:12 months post-surgery.
|
12 months post-surgery.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change from baseline in Wexner score.
大体时间:12 months post surgery
|
The change from baseline in the total Wexner Incontinence Score (range 0-20) at each follow-up visit.
A higher score means worse outcome.
|
12 months post surgery
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (估计的)
2026年6月1日
初级完成 (估计的)
2028年7月31日
研究完成 (估计的)
2029年7月31日
研究注册日期
首次提交
2026年5月24日
首先提交符合 QC 标准的
2026年6月15日
首次发布 (实际的)
2026年6月17日
研究记录更新
最后更新发布 (实际的)
2026年6月17日
上次提交的符合 QC 标准的更新
2026年6月15日
最后验证
2026年5月1日
更多信息
与本研究相关的术语
其他研究编号
- 202600564A3
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
不
IPD 计划说明
Individual participant data (IPD) will not be shared due to strict restrictions imposed by our Institutional Review Board (IRB) and local data privacy regulations.
These policies prohibit the external dissemination or public sharing of patient-level data to ensure the utmost protection of patient confidentiality and privacy.
Only aggregated data will be shared through scientific publications.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
不
研究美国 FDA 监管的设备产品
不
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.